Hyperion Therapeutics to Present at the Annual Stifel 2013 Healthcare
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Hyperion
Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to
present at the annual Stifel 2013 Healthcare Conference on Thursday, September
12 at 9:45 a.m. ET.
Jeffrey Farrow, Chief Financial Officer will provide a company overview. To
access the live webcast and subsequent archived recording, please visit
Hyperion's website at http://investors.hyperiontx.com/events.cfm.
About Hyperion Therapeutics
Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company
committed to developing and delivering life-changing treatments for orphan
diseases and hepatology. The company's first commercial product, RAVICTI®
(glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is
currently being marketed in the United States. The company also owns and
markets BUPHENYL® (sodium phenylbutyrate) Tablets and Powder worldwide. For
more information, please visit www.hyperiontx.com.
CONTACT: Sylvia Wheeler, Investor Relations
Press spacebar to pause and continue. Press esc to stop.